What's Happening?
Outlook Therapeutics has received FDA approval for Lytenava, a novel formulation of the VEGF inhibitor bevacizumab, for the treatment of wet age-related macular degeneration (AMD). This approval follows three previous complete response letters from the FDA,
with the last one in December 2025. The FDA's Office of New Drugs accepted data from Outlook's NORSE TWO and NORSE EIGHT studies, along with supplemental information, to support the drug's efficacy. Lytenava is the first FDA-approved version of bevacizumab for wet AMD, providing a new treatment option for this leading cause of vision loss among older adults.
Why It's Important?
The approval of Lytenava offers a new, FDA-approved treatment option for wet AMD, a condition that significantly impacts the quality of life for older adults. This approval provides ophthalmologists with a purpose-built formulation of bevacizumab, designed specifically for intravitreal administration, ensuring manufacturing consistency and regulatory oversight. The introduction of Lytenava into the market could enhance treatment accessibility and potentially improve outcomes for patients with wet AMD.
What's Next?
Outlook Therapeutics plans to launch Lytenava in the US by the end of the year. The company will focus on marketing and distribution strategies to ensure the drug reaches patients in need. Additionally, Outlook may explore further clinical studies to expand the indications for Lytenava and assess its long-term efficacy and safety. The approval also sets a precedent for other companies seeking to develop ophthalmic formulations of existing drugs, potentially leading to more treatment options for various eye conditions.
